ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

NNC4004-0002

A development code.

Its studies are mostly in Hyperuricemia, led by Novo Nordisk.

Furthest: phase 1, since Feb 27, 20251 company-led study, 1 open or runningNext primary completion: Jan 19, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordisk11 open or runningphase 1since Feb 27, 2025Feb 27, 2025Jan 19, 2027phase 1 · NCT06859073

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 27, 2025First study: phase 1 study in HyperuricemiaFirst studyNCT06859073 · 50 enrolled · United States
  2. Oct 26, 2026Primary completion moved from 2026-06-01 to 2027-01-19Date moved laterphase 1 · +8 months · NCT06859073

Ahead

  1. Jan 19, 2027Primary completion: phase 1 study in HyperuricemiaNCT06859073

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06859073Hyperuricemia · United States1Active, not recruitingJan 19, 202750

How it is read

Names in the registry

  • “NNC4004-0002”, 1 entry

Codes read as this program: NNC40040002.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.